Prostate Cancer

Emmanuel S. Antonarakis, MBBCh, discusses the design of a randomized phase II study of sipuleucel-T with or without radium-223 dichloride in men with asymptomatic bone-metastatic castrate-resistant prostate cancer.

Neeraj Agarwal, MD, discusses data from a posthoc analysis of the phase III TITAN trial in patients with metastatic castration-sensitive prostate cancer.

Rana R. McKay, MD, discusses the utility of radium-223 in metastatic castration-resistant prostate cancer.

Himisha Beltran, MD, discusses the utility of liquid biopsies versus tissues biopsies in castration-resistant neuroendocrine prostate cancer.

William K. Oh, MD, discusses the role of radiopharmaceuticals in metastatic castration-resistant prostate cancer.

Petros Grivas, MD, PhD, discusses potential combination regimens with cabazitaxel in prostate cancer.

Wolfgang Fendler, MD, discusses the rationale for creating the 68Ga-PSMA-11 PET in prostate cancer.

A subset of patients with metastatic castration-resistant prostate cancer who have low tumor mutational burden may benefit from checkpoint inhibition with ipilimumab if the tumor has a high density of CD8-positive T cells and increased interferon-interferon gamma signaling.

Leonard G. Gomella, MD, professor, chair of the Department of Urology, and director of the Sidney Kimmel Cancer Center Network, of Thomas Jefferson University Hospital, discusses the potential impact of targeted therapy approvals on the use of genetic testing in prostate cancer.

Nonmetastatic castration-resistant prostate cancer is a more recently defined clinical state of prostate cancer, for which several approved drugs are now available.

The use of PARP inhibitors against DNA damage repair alterations in prostate cancer is the first display of the potential for widespread precision medicine in the field.